Lifestyle News

TOKYO (AP) — Starting out with funny videos and chat over Mario Kart racing games, two Ukrainian brothers have added a somber tone to their YouTube channel popular with young Japanese with updates from their country that bring the harsh realities of

PORTLAND, Maine (AP) — The worldwide seafood industry is steeling itself for price hikes, supply disruptions and potential job losses as new rounds of economic sanctions on Russia make key species such as cod and crab harder to come by.

The latest hero from Marvel is hard to explain. He's a man and yet also a bat. No, not Batman. Let me try again: He's a daywalking vampire, but, no, not that cool cat Blade. This guy is good but also very bad.

With no running water and only a wood stove to heat his remote Quebec cabin, Mark Hogben starts each morning by making a fire and boiling lake water.

NEW YORK (AP) — Bobby Moynihan, the former “Saturday Night Live” star, is now a member of another inner circle of comedy: those writing children's books. Moynihan's picture story “Not All Sheep Are Boring!” will be published Sept.

The cost of everything keeps creeping up. And if you happen to have credit card debt, that’s about to get a bit more expensive too, thanks to a series of interest rate increases beginning this month.

LONDON (AP) — The pharmaceutical developer Novavax says it has asked the European Medicines Agency to extend the authorization of its coronavirus vaccine to children aged 12 to 17 amid a surge of disease across the continent.

BOSTON (AP) — Chris Rock received several standing ovations before he told one joke Wednesday at his first comedy show since Will Smith slapped him in the face onstage at the Oscars.

NEW YORK (AP) — The Academy of Motion Pictures Arts and Sciences on Wednesday said that Will Smith was asked to leave Sunday's Oscar ceremony after hitting Chris Rock but refused to do so.

WASHINGTON (AP) — Federal health advisers on Wednesday narrowly ruled against an experimental drug for the debilitating illness known as Lou Gehrig’s disease, a potential setback for patient groups who have lobbied for the medication’s approval.